Medeon Biodesign Wins FDA OK for Abclose - Laparoscopic Port Site Closure Device

TAIPEI, Taiwan, Sept. 19, 2016 /PRNewswire/ -- Medeon Biodesign, Inc., a Taiwan medical device company, announces today that the company has received U.S. Food and Drug Administration 510(k) clearance for AbClose^TM, a single use, disposable laparoscopic port site closure device. AbClose^TM is a revolutionary advancement in port site closure technology that enables fast, simple, and secure single-operator suturing and eliminates the majority of user variability.

"AbClose^TM is designed to reduce time, cost, and risk of port site closure and minimize the frustrations experienced by surgical teams at the end of the surgical procedure. AbClose^TM enables secure and precise delivery of 180-degree suture bites on fascia of nearly all thicknesses. It is estimated that 2.8 million laparoscopic procedures are performed in the US and approximately 7.5 million procedures are performed worldwide each year. AbClose^TM addresses the unmet need of virtually every laparoscopic surgery," said Dr. Yue-Teh Jang, Chairman and CEO of Medeon Biodesign.

"Port site hernias are sometimes difficult to diagnose and repair, and the best approach is preventative. Thus, there is a significant clinical need for safe, rapid, and reliable large port site closure in prevention of hernias. AbClose^TM provide a predictable solution to allow surgeons to quickly, precisely, and securely suture trocar sites in under a minute. It functions similarly to a sewing machine and provides air-tight closure with predictive suture return," said Dr. Harcharan Gill, Professor of Urology at Stanford at Stanford University School of Medicine.

"Complications of port site hernias can result in incisional pain or bowel strangulation, causing significantly longer recovery time and increased treatment cost to patients and hospitals," said Dr. Kirby Tran, a practicing Obstetrician & Gynecologist in Mountain View, California. "AbClose^TM requires minimal training, and significantly reduces the total time, cost, risks, and frustration associated with ineffective port site closure. AbClose^TM is very simple to use."

About Medeon Biodesign

Medeon Biodesign is a publicly traded company (Taipei Exchange Ticker: 6499) located in Taipei, Taiwan and with a subsidiary in Los Altos, California. The company focuses on the development of medical devices for minimally invasive surgeries to treat diseases of sizable patient population, such as cardiovascular, peripheral vascular, orthopedic, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery. For more information, please visit www.medeonbio.com/en.

For further information, please contact:

Dr. Yi-Ju Chen
+886.2.2881.6686
ir@medeonbio.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medeon-biodesign-receives-fda-510k-clearance-for-abclosetm---laparoscopic-port-site-closure-device-300329926.html

SOURCE Medeon Biodesign